Video
Dr. Choueiri on Trials Investigating Combination Regimens for RCC
Author(s):
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).
Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).
There is a promising phase III trial combining axitinib (Inlyta) with pembrolizumab (Keytruda), explains Choueiri. The preliminary data from the phase I trial showed a high response rate of 71% for patients with RCC.
Additionally, there is a phase I study investigating the combination of lenvatinib (Lenvima) plus pembrolizumab, which has shown exciting activity, states Choueiri. This combination will also be compared with levantinib plus everolimus (Afinitor) in patients with RCC.
